|
|
73 Watling Street
London, EC4M 9BJ UK
phone:(020) 7153 4920
fax:(020) 7153 4921
|
|
| Symbol |
RGT |
| Exchange |
LSE |
| Founded |
1981 |
| Employees |
|
|
|
| www.regentherapeutics.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Neurodegenerative illness treatment |
|
| Management |
| Percy Lomax BSc, Executive Chairman; Norman Lott BSc ACA, Finance Director and Company Secretary; Martin Small, New Projects Director; Timothy Shilton BSc Hons, Development Director; Dr Peter Garrod BDS, Non-Executive Director |
| |
|
|
|
|
|
|
|
| Keywords |
| colostrinin, pharmaceutical, peptides, veterinary colostrinin |
|
|
|
| Description |
|
ReGen Therapeutics Plc was formed in February 1998 to develop Colostrinin, a proline-rich polypeptide complex derived from mammalian colostrum. The complex and the peptides within it are viewed as having potential utility in neurodegenerative illnesses such as Alzheimer’s disease, Parkinson’s Disease, Multiple Sclerosis and Amyotrophic Lateral Sclerosis. In addition to the Colostrinin project, in February 2006 ReGen acquired the rights to develop a new use for the long-established pharmaceutical drug zolpidem for the treatment of brain dormancy/diaschesis from a UK-based company Sciencom Ltd. The Company’s shares were admitted to trading on the London OFEX market in December 1998. ReGen floated on the Alternative Investment Market of the London Stock Exchange in March 2000, where the shares continue to be quoted and actively traded. The Company applied to the US SEC for a trading facility on the New York OTCQX market at the end of 2007 and anticipates that its shares will become tradeable, as American Depositary Receipts, in early 2008. |
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members
